CARACTERÍSTICAS DE PACIENTES CON ENFERMEDAD PULMONAR INTERSTICIAL ASOCIADA A ENFERMEDADES DE TEJIDO CONECTIVO EN LA CAJA DE SEGURO SOCIAL. PANAMÁ.

Lorena Noriega-Aguirre; Ilsa Moreno-Del Cid; Rolando Reyna

Enviado octubre 30, 2024

Publicado 2026-02-02

Artículos de Investigación

Vol. 34 Núm. 2 (2021): Revista Médico Científica

CARACTERÍSTICAS DE PACIENTES CON ENFERMEDAD PULMONAR INTERSTICIAL ASOCIADA A ENFERMEDADES DE TEJIDO CONECTIVO EN LA CAJA DE SEGURO SOCIAL. PANAMÁ.

Lorena Noriega-Aguirre⁺⁻
Ilsa Moreno-Del Cid⁺⁻
Rolando Reyna⁺⁻

PDF

Citación:

DOI: ND

Publicado: 2026-02-02

Derechos de autor 2024 Revista médico científica

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Resumen

INTRODUCCIÓN: La enfermedad pulmonar intersticial difusa asociada a enfermedades de tejido conectivo es la causa más común de las neumonías intersticiales. El objetivo fue describir las características de los pacientes con enfermedad de tejido conectivo que presentan enfermedad pulmonar intersticial.

MATERIALES Y MÉTODOS: Estudio descriptivo y retrospectivo en pacientes con enfermedad pulmonar intersticial asociada a enfermedades del tejido conectivo, con diagnósticos establecidos entre el 2015 y el 2019, en la Caja de Seguro Social de Panamá.

RESULTADOS: Se analizaron 38 casos, en su mayoría pacientes del sexo femenino (81.58 %), con edad promedio de 57 años. La esclerosis sistémica y la artritis reumatoidea fueron las enfermedades de colágeno más frecuentes, con 21.05 % cada una. La disnea, presentada por el 96.84 %, y la tos en el 60.53 %, fueron los síntomas respiratorios más frecuentes. Los anticuerpos más frecuentes fueron los antinucleares en el 34.21 %, Anti-Ro y el factor reumatoideo en el 18.42 % de los casos. El patrón tomográfico de neumonía intersticial no específica se encontró en el 34.21 % de los casos, y el valor promedio de la difusión de monóxido de carbono fue del 56 % del valor esperado. Los esteroides (50 %) y la azatioprina (38.24 %) fueron los tratamientos más utilizados.

CONCLUSIÓN: Las enfermedades del tejido conectivo más relacionadas con enfermedad pulmonar intersticial fueron la esclerosis sistémica y la artritis reumatoidea. Los síntomas respiratorios son inespecíficos; la difusión de monóxido de carbono y un patrón de neumonía intersticial no específica contribuyen al diagnóstico.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

BIBLIOGRAFÍA
Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Intertitial Lung disease. Eur Respir Rev. 2014;23(131):40-54.
Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial lung disease in the connective tissue diseases. Clin Chest Med. 2012;33(1):123-49.
Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015;24(136):216-38.
Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40(2):78-83.
Nair A, Walsh SL, Desai SR. Imaging of pulmonary involvement in rheumatic disease. Rheum Dis Clin North Am. 2015;41(2):167-96.
Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007;28(4):369-78.
Gómez Carrera L, Bonilla Hernan G. Pulmonary manifestations of collagen diseases. Arch Bronconeumol. 2013;49(6):249-60.
Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol. 2015;34(1):99-105.
Miguel-Reyes JL, Gochicoa-Rangel L, Pérez-Padilla R, Torre-Bouscoulet L. Functional respiratory assessment in interstitial lung disease. Rev Invest Clin. 2015;67(1):5-14.
Raghu G, Brown KK. Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. Clin Chest Med. 2004;25(3):409-19.
Kadoch MA, Cham MD, Beasley MB, Ward TJ, Jacobi AH, Eber CD, et al. Idiopathic interstitial pneumonias: a
radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society
classification system. Curr Probl Diagn Radiol. 2015;44(1):15-25.
Koelsch TL, Chung JH, Lynch DA. Radiologic evaluation of idiopathic interstitial pneumonias. Clin Chest Med. 2015;36(2):269-82.
Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a
randomised, controlled trial. Lancet Respir Med. 2014;2(4):277-84.
Kalluri M, Claveria F, Ainsley E, Haggag M, Armijo-Olivo S, Richman-Eisenstat J. Beyond Idiopathic Pulmonary Fibrosis Diagnosis: Multidisciplinary Care With an Early Integrated Palliative Approach Is Associated With a Decrease in Acute Care Utilization and Hospital Deaths. J Pain Symptom Manage. 2018;55(2):420-426.
Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219-227.
Fernandes L, Nasser M, Ahmad K, Cottin V. Interstitial Pneumonia With Autoimmune Features (IPAF). Front Med.
;6:209.
Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Colaci M, Pavone M, et al. Clinical, serological and radiological
features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. Respir Med.
;150:154-160.
Sebastiani M, Faverio P, Manfredi A, Cassone G, Vacchi C, Stainer A, et al. Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. Biomedicines. 2020;9(1):17.
Capobianco J, Grimberg A, Thompson BM, Antunes VB, Jasinowodolinski D, Meirelles GS. Thoracic manifestations
of collagen vascular diseases. Radiographics. 2012;32(1):33-50.
Koelsch TL, Chung JH, Lynch DA. Radiologic evaluation of idiopathic interstitial pneumonias. Clin Chest Med. 2015;36(2):269-82.
Caron M, Hoa S, Hudson M, Schwartzman K, Steele R. Pulmonary function tests as outcomes for systemic
sclerosis interstitial lung disease. Eur Respir Rev. 2018.15;27(148):170102.
Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive Decline of Lung Function in
Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2017;69(3):542-549.
Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-Term Pulmonary Function Trends
Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol.
;69(8):1670-1678.
Cottin V, Valenzuela C. Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. Presse Med. 2020;49(2):104021.
Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320.
Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689-98.
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ.
; 352: h6819.
Fagundes MN, Caleiro MT, Navarro-Rodriguez T, Baldi BG, Kavakama J, Salge JM, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med. 2009;103(6):854-60.
Hershcovici T, Jha LK, Johnson T, Gerson L, Stave C, Malo J, et al. Systematic review: the relationship between
interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34(11-12):1295-305.

Palabras clave

PDF

Resumen visto - 9 veces
PDF descargado - 3

Licencia

Content Top

[1] BIBLIOGRAFÍA

[2] Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Intertitial Lung disease. Eur Respir Rev. 2014;23(131):40-54.

[3] Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial lung disease in the connective tissue diseases. Clin Chest Med. 2012;33(1):123-49.

[4] Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015;24(136):216-38.

[5] Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40(2):78-83.

[6] Nair A, Walsh SL, Desai SR. Imaging of pulmonary involvement in rheumatic disease. Rheum Dis Clin North Am. 2015;41(2):167-96.

[7] Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007;28(4):369-78.

[8] Gómez Carrera L, Bonilla Hernan G. Pulmonary manifestations of collagen diseases. Arch Bronconeumol. 2013;49(6):249-60.

[9] Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol. 2015;34(1):99-105.

[10] Miguel-Reyes JL, Gochicoa-Rangel L, Pérez-Padilla R, Torre-Bouscoulet L. Functional respiratory assessment in interstitial lung disease. Rev Invest Clin. 2015;67(1):5-14.

[11] Raghu G, Brown KK. Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. Clin Chest Med. 2004;25(3):409-19.

[12] Kadoch MA, Cham MD, Beasley MB, Ward TJ, Jacobi AH, Eber CD, et al. Idiopathic interstitial pneumonias: a

[13] radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society

[14] classification system. Curr Probl Diagn Radiol. 2015;44(1):15-25.

[15] Koelsch TL, Chung JH, Lynch DA. Radiologic evaluation of idiopathic interstitial pneumonias. Clin Chest Med. 2015;36(2):269-82.

[16] Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a

[17] randomised, controlled trial. Lancet Respir Med. 2014;2(4):277-84.

[18] Kalluri M, Claveria F, Ainsley E, Haggag M, Armijo-Olivo S, Richman-Eisenstat J. Beyond Idiopathic Pulmonary Fibrosis Diagnosis: Multidisciplinary Care With an Early Integrated Palliative Approach Is Associated With a Decrease in Acute Care Utilization and Hospital Deaths. J Pain Symptom Manage. 2018;55(2):420-426.

[19] Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219-227.

[20] Fernandes L, Nasser M, Ahmad K, Cottin V. Interstitial Pneumonia With Autoimmune Features (IPAF). Front Med.

[21] ;6:209.

[22] Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Colaci M, Pavone M, et al. Clinical, serological and radiological

[23] features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. Respir Med.

[24] ;150:154-160.

[25] Sebastiani M, Faverio P, Manfredi A, Cassone G, Vacchi C, Stainer A, et al. Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. Biomedicines. 2020;9(1):17.

[26] Capobianco J, Grimberg A, Thompson BM, Antunes VB, Jasinowodolinski D, Meirelles GS. Thoracic manifestations

[27] of collagen vascular diseases. Radiographics. 2012;32(1):33-50.

[28] Koelsch TL, Chung JH, Lynch DA. Radiologic evaluation of idiopathic interstitial pneumonias. Clin Chest Med. 2015;36(2):269-82.

[29] Caron M, Hoa S, Hudson M, Schwartzman K, Steele R. Pulmonary function tests as outcomes for systemic

[30] sclerosis interstitial lung disease. Eur Respir Rev. 2018.15;27(148):170102.

[31] Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive Decline of Lung Function in

[32] Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2017;69(3):542-549.

[33] Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-Term Pulmonary Function Trends

[34] Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol.

[35] ;69(8):1670-1678.

[36] Cottin V, Valenzuela C. Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. Presse Med. 2020;49(2):104021.

[37] Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320.

[38] Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689-98.

[39] Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ.

[40] ; 352: h6819.

[41] Fagundes MN, Caleiro MT, Navarro-Rodriguez T, Baldi BG, Kavakama J, Salge JM, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med. 2009;103(6):854-60.

[42] Hershcovici T, Jha LK, Johnson T, Gerson L, Stave C, Malo J, et al. Systematic review: the relationship between

[43] interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34(11-12):1295-305.

Imagen de portada

Resumen

Descargas

Citas

Palabras clave

Licencia